TOP1 Good Quality Hormone Peptides Teriparatide Acetate CAS 52232-67-4 Teriparatide

Product Description

Introduction:

Teriparatide Acate is a synthetic of human parathyroid hormone (PTH). It is derived from the 34 amino acids of the full-length PTH and is used in the treatment of osteoporosis.

Function:

Teriparatide Acetate is primarily used to increase bone formation and improve bone density in individuals with osteoporosis. It works by stimulating osteoblast activity, which are the cells responsible for bone formation. By promoting new bone growth, Teriparatide Acetate helps to reduce the risk of fractures and strengthens the skeletal structure. Additionally, it increases calcium absorption from the intestines and enhances renal reabsorption of calcium, contributing to overall bone health.

Application:

Teriparatide Acetate is administered through daily subcutaneous injections, typically for a duration of up to 24 months. It is prescribed to postmenopausal women and men with a high risk of fractures or those who have failed or are intolerant to other available osteoporosis treatments. Teriparatide Acetate is also used in the treatment of glucocorticoid-induced osteoporosis, a condition caused by long-term use of glucocorticoid medications. Additionally, it may be prescribed to individuals with primary or hypogonadal osteoporosis. Regular monitoring of bone density and calcium levels is essential during treatment with Teriparatide Acetate to ensure its efficacy and safety.

Molecular structure
Teriparatide is a synthetic 34-peptide, the 1-34 amino acid segment of human parathyroid hormone PTH, which is the biologically active N-terminal region of endogenous 84-amino acid parathyroid hormone PTH. The immunological and biological properties of this product are identical to those of endogenous parathyroid hormone PTH and bovine parathyroid hormone PTH(bPTH).

pharmacokinetics
The absorption and elimination rate of teriparatide were rapid after subcutaneous injection. Subcutaneous injection of Teriparatide was 20μg, the peak time (tmax) was 30min, the half-life (t1/2) was 60min, the half-life of intravenous serum was 5min, and the absolute bioavailability was 95%. 90% of the drug is cleared by the kidneys.

Adverse reactions and safety
The common adverse reactions after teriparatide injection included dizziness, back pain, nausea and lower limb spasm, which were mostly transient. Rare adverse reactions include arrhythmia and deafness. At present, Chemicalbook believes that there is no significant relationship between the occurrence of adverse reactions and patient age and dose.

Action mechanism
Teriparatide can mediate bone metabolism by inhibiting osteoblast apoptosis, activating bone lining cells and enhancing osteoblast differentiation. The PHT-Ⅰ receptor on the surface of osteoblasts, bone lining cells and bone marrow stromal stem cells was stimulated intermittently by modulating the adenylate cyclase-cyclic adenosine-protein kinase A pathway to promote the differentiation of osteoblasts and prolong the lifespan of osteoblasts. The proliferation of osteoblast cell lines was stimulated by phosphater-C-cytoplasmic calcium ion protein kinase C signaling pathway. By inhibiting the trans-activation activity of PPARγ, the differentiation of stromal cells into adipocyte lines was reduced, and the number of osteoblasts was increased. Indirectly regulate bone growth by regulating cytokines, for example, iGF-1 can be induced to bind to osteoblasts, thereby promoting bone formation; The process of bone formation is regulated by Wnt signaling pathway, thereby increasing bone formation.